Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses-Reference-Cited by-同舟云学术

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre‐specified and post hoc analyses

Published:2022-06-03 Issue:1 Volume:66 Page:39-49
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle and Nerve

Author:

Miller Robert G.¹,Zhang Rongzhen²,Bracci Paige M.³,Azhir Ari⁴,Barohn Richard⁵,Bedlack Richard⁶,Benatar Michael⁷,Berry James D.⁸,Cudkowicz Merit⁸,Kasarskis Edward J.⁹,Mitsumoto Hiroshi¹⁰,Manousakis Georgios¹¹,Walk David¹¹,Oskarsson Bjorn¹²,Shefner Jeremy¹³,McGrath Michael S.²⁴^ORCID

Affiliation:

1. California Pacific Medical Center San Francisco California USA

2. Department of Medicine University of California San Francisco San Francisco California USA

3. Department of Epidemiology and Biostatistics University of California San Francisco San Francisco California USA

4. Neuvivo, Inc. Palo Alto California USA

5. University of Missouri Columbia Missouri USA

6. Duke University Medical Center Durham North Carolina USA

7. University of Miami Miller School of Medicine Miami Florida USA

8. Massachusetts General Hospital Boston Massachusetts USA

9. University of Kentucky Lexington Kentucky USA

10. Columbia University Medical Center New York New York USA

11. University of Minnesota Medical School Minneapolis Minnesota USA

12. Department of Neurology Mayo Clinic Florida USA

13. Barrow Neurological Institute University of Arizona College of Medicine Phoenix, Creighton University College of Medicine Phoenix Phoenix Arizona USA

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27511

Reference27 articles.

1. Amyotrophic lateral sclerosis

2. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

3. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS

4. Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis

5. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model;Molecular Therapy - Methods & Clinical Development;2024-09

2. Meta-analysis of differential gene expression in lower motor neurons isolated by laser capture microdissection from post-mortem ALS spinal cords;Frontiers in Genetics;2024-04-16

3. Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials;Cells;2024-03-05

4. New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases;International Journal of Molecular Sciences;2024-02-26

5. The Effectiveness of NP001 on Long Term Survival of Patients with Amyotrophic Lateral Sclerosis: The IKARIA Study;2024